HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michael J Fisher Selected Research

Neurofibromatoses (Neurofibromatosis)

1/2022Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1.
1/2021Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children.
1/2021Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
1/2021NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
10/2020A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study.
1/2019Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
1/2019First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics.
1/2018Validation of an automated tractography method for the optic radiations as a biomarker of visual acuity in neurofibromatosis-associated optic pathway glioma.
1/20182016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
6/2017The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michael J Fisher Research Topics

Disease

27Neoplasms (Cancer)
11/2022 - 06/2002
24Glioma (Gliomas)
01/2022 - 04/2007
13Neurofibromatosis 1 (Neurofibromatosis Type I)
11/2022 - 07/2009
13Neurofibromatoses (Neurofibromatosis)
01/2022 - 06/2012
9Plexiform Neurofibroma
11/2022 - 04/2008
8Medulloblastoma
11/2021 - 12/2004
7Brain Neoplasms (Brain Tumor)
10/2021 - 11/2002
4Schwannomatosis
01/2022 - 03/2014
3Neurofibromatosis 2 (Neurofibromatosis Type II)
01/2022 - 01/2018
3Exanthema (Rash)
01/2020 - 12/2016
3Hearing Loss (Hearing Impairment)
12/2019 - 04/2014
2Pain (Aches)
01/2021 - 01/2021
2Disease Progression
01/2020 - 05/2013
2Pinealoma (Pineoblastoma)
01/2020 - 01/2020
2Meningioma (Meningiomas)
01/2019 - 06/2017
2Astrocytoma (Pilocytic Astrocytoma)
01/2019 - 10/2014
2Ototoxicity
04/2014 - 12/2004
1Cancer Pain
11/2022
1Hypothyroidism
01/2021
1Fatigue
01/2021
1Nausea
01/2020
1Vomiting
01/2020
1Diarrhea
01/2020
1Paronychia
01/2020
1Acoustic Neuroma (Acoustic Neurinoma)
12/2019
1Hamartoma
01/2019
1Epiretinal Membrane (Epiretinal Membranes)
01/2019
1Cardiotoxicity
01/2018
1Legius syndrome
01/2018
1Musculoskeletal Abnormalities
01/2018
1Neurilemmoma (Schwannoma)
01/2018
1Neuroblastoma
06/2017
1Sarcoma (Soft Tissue Sarcoma)
06/2017
1Neurofibroma
12/2016
1Apnea
08/2016
1Hypersensitivity (Allergy)
01/2016
1Hemolytic Anemia
11/2014
1Deafness (Deaf Mutism)
06/2014
1Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
06/2013
1Hypertension (High Blood Pressure)
05/2013
1Proteinuria
05/2013
1Sleepiness
05/2013
1Arthritis (Polyarthritis)
05/2013
1Stroke (Strokes)
11/2012
1Carcinogenesis
11/2009

Drug/Important Bio-Agent (IBA)

8Biological ProductsIBA
01/2021 - 06/2013
7Biomarkers (Surrogate Marker)IBA
11/2021 - 11/2013
6Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
11/2022 - 11/2009
6AZD 6244IBA
11/2022 - 12/2016
3Uvitex SWN (SWN)IBA
01/2022 - 06/2017
3Retinaldehyde (Retinal)IBA
01/2022 - 03/2011
3Creatine Kinase (Creatine Phosphokinase)IBA
01/2020 - 12/2016
3Bevacizumab (Avastin)FDA Link
12/2019 - 07/2009
3Sirolimus (Rapamycin)FDA Link
06/2015 - 06/2014
3Cisplatin (Platino)FDA LinkGeneric
06/2014 - 12/2004
2Proteins (Proteins, Gene)FDA Link
01/2021 - 11/2010
2EverolimusFDA Link
01/2021 - 10/2020
2Mitogen-Activated Protein KinasesIBA
01/2018 - 12/2016
2Neurofibromin 1 (Neurofibromin)IBA
01/2018 - 06/2014
2Carboplatin (JM8)FDA LinkGeneric
01/2016 - 11/2014
2Vincristine (Oncovin)FDA LinkGeneric
11/2014 - 12/2004
2Amifostine (Ethyol)FDA LinkGeneric
06/2014 - 12/2004
1Cell-Free Nucleic AcidsIBA
11/2021
1mirdametinibIBA
01/2021
1CytokinesIBA
01/2021
1cabozantinibIBA
01/2021
1TOR Serine-Threonine KinasesIBA
10/2020
1MTOR InhibitorsIBA
10/2020
1RNA (Ribonucleic Acid)IBA
01/2020
1Protons (Proton)IBA
12/2019
1Alkylating AgentsIBA
11/2019
1Dihydrotachysterol (AT 10)IBA
08/2016
1Cytochrome P-450 CYP3AIBA
06/2015
1Cyclic AMP (AMP, Cyclic)IBA
01/2015
1Adenylyl Cyclases (Adenylyl Cyclase)IBA
01/2015
1Pharmaceutical PreparationsIBA
11/2014
1AntibodiesIBA
11/2014
1Sorafenib (BAY 43-9006)FDA Link
10/2014
1dipinacoline glutamateIBA
06/2013
1TrypsinIBA
11/2010
1ProteomeIBA
11/2010
1Immunoglobulins (Immunoglobulin)IBA
07/2009
1Drug CombinationsIBA
07/2009
1Monoclonal AntibodiesIBA
07/2009
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2009

Therapy/Procedure

19Therapeutics
11/2022 - 08/2005
10Drug Therapy (Chemotherapy)
01/2022 - 12/2004
5Radiotherapy
01/2021 - 12/2004
5Aftercare (After-Treatment)
01/2021 - 10/2004
4Craniospinal Irradiation
01/2021 - 09/2015
2Adjuvant Chemotherapy
01/2021 - 12/2019
2Hearing Aids (Hearing Aid)
06/2014 - 04/2014
2Cranial Irradiation
04/2013 - 11/2012
1Anesthesia
01/2022
1General Anesthesia
01/2022
1Hematopoietic Stem Cell Transplantation
01/2022
1Drug Tapering
01/2021
1Proton Therapy
01/2018
1Withholding Treatment
05/2013
1Combination Drug Therapy (Combination Chemotherapy)
11/2009